- Investing.com
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
DefenCath's Triumph | CorMedix's stock soars 131% as DefenCath launch in hemodialysis market shows promising early adoption, with significant outpatient pull-through from small and mid-sized operators. |
Strategic Partnerships | Explore CorMedix's commercial agreements with dialysis providers, including one LDO and two MDOs, and potential negotiations with a top U.S. dialysis provider. |
Financial Trajectory | Delve into CorMedix's Q3 revenues of $5M and EBITDA outlook, with analyst price targets ranging from $11 to $19 per share and a consensus "Buy" recommendation. |
Growth Horizons | Learn about CorMedix's expansion plans for DefenCath beyond hemodialysis, targeting total parenteral nutrition and pediatric hemodialysis markets for future growth. |
Metrics to compare | CRMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRMDPeersSector | |
---|---|---|---|---|
P/E Ratio | 50.4x | −3.1x | −0.5x | |
PEG Ratio | 0.39 | 0.02 | 0.00 | |
Price/Book | 7.5x | 2.2x | 2.6x | |
Price / LTM Sales | 10.5x | 2.1x | 3.3x | |
Upside (Analyst Target) | 71.8% | 171.1% | 45.4% | |
Fair Value Upside | Unlock | 23.3% | 7.7% | Unlock |